| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/12/2004 | US20040156866 Leishmania infantum P36 protein or immunogenic fragment optionally in combination with a compound stimulating the production of a Th1-type cellular immune response |
| 08/12/2004 | US20040156865 M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever |
| 08/12/2004 | US20040156864 Immunogenic HBc chimer particles having enhanced stability |
| 08/12/2004 | US20040156863 administering chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles |
| 08/12/2004 | US20040156862 Novel hepatitis C virus peptides and uses thereof |
| 08/12/2004 | US20040156860 T-cell vaccination for the treatment of multiple sclerosis |
| 08/12/2004 | US20040156858 yeast vehicle; and a fusion protein of a cancer antigen and a peptide having amino acid residues that are heterologous to the cancer antigen that stabilizes expression of the fusion protein or prevents posttranslational modification |
| 08/12/2004 | US20040156856 adding a labeled antibody, which binds to the autoinducer having a homoserine lactone ring with an N-acyl side chain, to a lysine-containing protein, and detection of immunospecific binding; N-(3-oxododecanoyl)-L-homoserine lactone |
| 08/12/2004 | US20040156854 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| 08/12/2004 | US20040156848 Therapeutic uses of factors which inhibit or neutralize MIF activity |
| 08/12/2004 | US20040156841 Human amine transporter |
| 08/12/2004 | US20040156840 A preferred IgM is autoantigen IgM, in particular anti-ds-DNA and anti-phospholipid IgM; may be mixed with an antiinflammatory agent, an immunosuppressive agent and/or a cytostatic agent |
| 08/12/2004 | US20040156839 blocking the interaction of IgG with FC gamma R and blocking the interaction of IgE with Fc epsilon RI or IgA with Fc alpha RI; treatment of: autoimmune disease such as lupus, autoimmune glomerulonephritis and immune thrombocytopenic purpura |
| 08/12/2004 | US20040156838 inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination; inducing a combined antibody and CTK response specific for IgE |
| 08/12/2004 | US20040156829 Transformed bacteria producing CS6 antigens as vaccines |
| 08/12/2004 | US20040156825 Short immunomodulatory oligonucleotides |
| 08/12/2004 | US20040156821 an antigen and a cytokine or inducing agent used to bias T cell responses away from Th1 or Th2 responses at the stage of antigen/APC encounter and/or at the stage of APC/T cell encounter; management of autoimmune disorders, allergy, and asthma |
| 08/12/2004 | US20040156820 Adjuvant combination formulations |
| 08/12/2004 | DE10303697A1 Using the third extracellular loop of the MC4 receptor in screening for pharmaceutical agents, e.g. for diagnosis, prevention or treatment of obesity, also new mutated MC4 receptors and their complexes |
| 08/12/2004 | CA2514580A1 Compositions and methods of tolerizing a primate to an antigen |
| 08/12/2004 | CA2514330A1 Mucosal meningococcal vaccines |
| 08/12/2004 | CA2514226A1 Use of anti-cd100 antibodies |
| 08/12/2004 | CA2514177A1 Tolerance-induced targeted antibody production |
| 08/12/2004 | CA2514125A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514117A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514062A1 Compositions and methods for treating cancer using igsf9 and liv-1 |
| 08/12/2004 | CA2513769A1 Method for evaluating the efficacy of certain cancer treatments |
| 08/12/2004 | CA2512174A1 Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof |
| 08/12/2004 | CA2511927A1 Method of preparing a vaccine and anti-tumor vaccines |
| 08/12/2004 | CA2510482A1 Recombinant hepatitis a virus antigens obtained in plant cells |
| 08/11/2004 | EP1445615A1 Method for discrimination between infectious and noninfectious prions |
| 08/11/2004 | EP1445317A2 Compositions and methods for the diagnosis and treatment of tumor |
| 08/11/2004 | EP1444989A1 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 08/11/2004 | EP1444987A2 Oral vaccine against diarrhea |
| 08/11/2004 | EP1444523A2 Screening for hepatitis c virus entry inhibitors |
| 08/11/2004 | EP1444350A2 Hiv-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof |
| 08/11/2004 | EP1444349A2 Process for the preparation of ramipril |
| 08/11/2004 | EP1444267A2 Affinity enhancement agents |
| 08/11/2004 | EP1444261A2 Immunogenic alk (anaplastic lymphoma kinase) peptides |
| 08/11/2004 | EP1444254A2 Molecules for disease detection and treatment |
| 08/11/2004 | EP1444250A1 Groel chimeric protein and vaccine |
| 08/11/2004 | EP1443971A2 METHOD OF USING 18080, A HUMAN SERINE CARBOXYPEPTIDASE FAMILY MEMBER |
| 08/11/2004 | EP1443963A2 Antibody targeting compounds |
| 08/11/2004 | EP1443962A2 Method for the treatment of cardiotoxicity induced by antitumor compounds |
| 08/11/2004 | EP1443961A2 Glycoprotein compositions |
| 08/11/2004 | EP1443960A2 Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases |
| 08/11/2004 | EP1443959A1 Salmonella vaccine |
| 08/11/2004 | EP1443958A2 Vaccine against infectious disease |
| 08/11/2004 | EP1443957A2 Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them |
| 08/11/2004 | EP1443913A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 08/11/2004 | EP1272044B1 Protein stabilised emulsions |
| 08/11/2004 | EP1242457B1 Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
| 08/11/2004 | EP1051187B9 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway |
| 08/11/2004 | EP0894135B1 Multivalent and multispecific antigen-binding protein |
| 08/11/2004 | EP0852491B1 Use of heparinases to decrease inflammatory responses |
| 08/11/2004 | EP0839050B1 Method of enhancing cell mediated immune responses |
| 08/11/2004 | EP0821728B1 Tie-2 ligands, methods of making and uses thereof |
| 08/11/2004 | EP0779922B1 Modified human c3 proteins |
| 08/11/2004 | EP0730648B1 HUMAN MUTATOR GENE hMSH2 AND HEREDITARY NON POLYPOSIS COLORECTAL CANCER |
| 08/11/2004 | EP0639985B1 Method and composition for preserving antigens and process for utilizing cytological material produced by same |
| 08/11/2004 | EP0629132B1 Purified vacuolating toxin from helicobacter pylori and methods to use same |
| 08/11/2004 | CN1520424A Immunoglobulins 2 |
| 08/11/2004 | CN1520421A Recombinant tumor specific antibody and use thereof |
| 08/11/2004 | CN1520320A Method of intradermally injecting substances |
| 08/11/2004 | CN1520318A Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 08/11/2004 | CN1520311A Cancer vaccine contg. cancer antigen based on tumor suppressor gene WT1 product and cationic liposomes |
| 08/11/2004 | CN1520304A Xenogenic oligo of or/and polyribonucleotides as agents for treatment of malignant twnours |
| 08/11/2004 | CN1520303A Turnor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 08/11/2004 | CN1519311A Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents |
| 08/11/2004 | CN1161469C Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
| 08/11/2004 | CN1161465C Chimeric proteins for use in transport of selected substance into cells |
| 08/11/2004 | CN1161460C Type-O hoof-and-mouth disease virus, type-O hoof-and-mouth disease vaccine with viurs and active component and prepn of the vaccine |
| 08/11/2004 | CN1161459C Recombinant adenovirus expressig human rotavirus VP7 and its preparing process and usage |
| 08/11/2004 | CN1161396C Biodegradable low molecular weight triblock polyester polyethylene glocol copolymers having reverse thermal gelation properties |
| 08/11/2004 | CN1161379C Novel peptides derived from autoantigent for use in immunitherapy of autoimmune diseases |
| 08/11/2004 | CN1161376C Major outer membrane protein CD of Moraxella |
| 08/11/2004 | CN1161154C Immunopotentiating formulations for vaccinal use |
| 08/11/2004 | CN1161153C Immobilized isomerous tumor vaccine and its preparing process |
| 08/11/2004 | CN1161152C Method and composition useful for inhibition of angiogenesis |
| 08/11/2004 | CN1161129C I(ex vivo) treatment of allogeneic and xanogeneic T-cells with gp39 antagonists |
| 08/11/2004 | CN1161110C Oral delayed immediate release formulation and method of preparation therefor |
| 08/10/2004 | US6774228 1,4,7,10-tetrazacyclododecanes capable of reacting with monoclonal or polyclonal antibody; imaging |
| 08/10/2004 | US6774227 Reating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (mif) |
| 08/10/2004 | US6774225 Antigenized antibody vaccine for foot-and-mouth disease |
| 08/10/2004 | US6774220 Compounds having lectinic properties and their biological applications |
| 08/10/2004 | US6774219 Candida albicans gene, integrin-like protein, antibodies, and methods of use |
| 08/10/2004 | US6774218 Drugs, vaccines |
| 08/10/2004 | US6774216 Antibody for use in diagnosis and treatment of immunological, inflammatory and nervous system disorders |
| 08/10/2004 | US6774123 Methods and compositions for inactivating viruses |
| 08/10/2004 | US6774119 Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
| 08/10/2004 | US6774117 MN gene and protein |
| 08/10/2004 | US6774116 Prodrugs via acylation with cinnamate |
| 08/10/2004 | US6774106 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
| 08/10/2004 | US6773916 Administering sub-immunological sized antigen-binding molecule (fc/fv fragments) |
| 08/10/2004 | US6773915 Detecting antibodies; culture product |
| 08/10/2004 | US6773908 From open reading frames; vaccines |
| 08/10/2004 | US6773900 End selection in directed evolution |
| 08/10/2004 | US6773891 Inducing the production of antibodies, in vivo, that specifically bind to nicotine. these conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. the novel conjugates preserve the chirality of nicotine in |
| 08/10/2004 | US6773881 By modulating vascular endothelial growth factor (vegf) |
| 08/10/2004 | US6773880 Bactericides; vaccine development; infection diagnosis; |